ITPA:c.94C>A and NUDT15:c.415C>T Polymorphisms and Their Relation to Mercaptopurine-Related Myelotoxicity in Childhood Leukemia in Thailand

References

• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Song TY, Lee SH, Kim G, Baek HJ, Hwang TJ, Kook H. Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia. Blood Res. 2018;53(1):25–34. doi:10.5045/br.2018.53.1.25
   Web of Science ®Google Scholar
• Shamoon RP, Ali MD, Shabila NP. Overview and outcome of Hodgkin’s lymphoma: experience of a single developing country’s oncology centre. PLoS One. 2018;13(4):e0195629. doi:10.1371/journal.pone.0195629
   PubMed Web of Science ®Google Scholar
• Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–2539. doi:10.3324/haematol.2020.247031
   PubMed Web of Science ®Google Scholar
• Fu Y, Wang H, Zhai X, et al. Improved outcome of newly diagnosed childhood mature B-cell lymphoma/leukemia with high tumor burden treated with BFM95-based protocol combining rituximab: a report from Shanghai, China. J Pediatr Hematol Oncol. 2019;41(3):170–174. doi:10.1097/MPH.0000000000001419
   Web of Science ®Google Scholar
• Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. Lancet Oncol. 2003;4(10):595–604. doi:10.1016/S1470-2045(03)01218-X
   Web of Science ®Google Scholar
• Rusu RA, Sirbu D, Curseu D, et al. Chemotherapy-related infectious complications in patients with Hematologic malignancies. J Res Med Sci. 2018;23:68. doi:10.4103/jrms.JRMS_960_17
   PubMed Web of Science ®Google Scholar
• Nelson JA, Carpenter JW, Rose LM, Adamson DJ. Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res. 1975;35(10):2872–2878.
   PubMed Web of Science ®Google Scholar
• Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1993;15(1):80–86. doi:10.1097/00043426-199302000-00010
   PubMedGoogle Scholar
• Ma XL, Wang B, Guo HY, et al. [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi. 2010;48(4):289–292. [Chinese].
   Google Scholar
• Albayrak M, Konyssova U, Kaya Z, et al. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2011;68(5):1155–1159. doi:10.1007/s00280-011-1599-7
   Web of Science ®Google Scholar
• Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2012;68(9):1233–1242. doi:10.1007/s00228-012-1251-4
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res. 2000;448(1):91–95. doi:10.1016/S0027-5107(00)00004-X
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9(1):37–42. doi:10.1097/00008571-199902000-00006
   PubMedGoogle Scholar
• Chang JG, Lee LS, Chen CM, et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics. 2002;12(3):191–195. doi:10.1097/00008571-200204000-00003
   PubMedGoogle Scholar
• Zhou H, Li L, Yang P, et al. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18(1):516. doi:10.1186/s12885-018-4398-2
   PubMed Web of Science ®Google Scholar
• Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab. 2005;85(4):271–279. doi:10.1016/j.ymgme.2005.03.011
   PubMed Web of Science ®Google Scholar
• Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341–348. doi:10.1007/s00280-018-3732-3
   PubMed Web of Science ®Google Scholar
• Gerbek T, Ebbesen M, Nersting J, Frandsen TL, Appell ML, Schmiegelow K. Role of TPMT and ITPA variants in mercaptopurine disposition. Cancer Chemother Pharmacol. 2018;81(3):579–586. doi:10.1007/s00280-018-3525-8
   PubMed Web of Science ®Google Scholar
• Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002;47(11):620–622. doi:10.1007/s100380200095
   Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373. doi:10.1038/ng.3508
   PubMed Web of Science ®Google Scholar
• Lu DY, Lu TR, Xu B, Ding J. Pharmacogenetics of cancer therapy: breakthroughs from beyond? Future Sci OA. 2015;1(4):FSO80. doi:10.4155/fso.15.80
   Google Scholar
• Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1(2):99–108. doi:10.1038/35101056
   Web of Science ®Google Scholar
• Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer. 2004;90(4):747–751. doi:10.1038/sj.bjc.6601574
   PubMed Web of Science ®Google Scholar
• Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NK. ITPA, TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in middle eastern children with acute lymphoblastic leukemia. Front Pharmacol. 2019;10:916. doi:10.3389/fphar.2019.00916
   PubMed Web of Science ®Google Scholar
• Singh M, Bhatia P, Khera S, Trehan A. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia. Leuk Res. 2017;62:17–22. doi:10.1016/j.leukres.2017.09.012
   PubMed Web of Science ®Google Scholar
• Stocco G, Crews KR, Evans WE. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf. 2010;9(1):23–37. doi:10.1517/14740330903426151
   PubMed Web of Science ®Google Scholar
• Wahlund M, Nilsson A, Kahlin AZ, et al. The role of TPMT, ITPA, and NUDT15 variants during mercaptopurine treatment of Swedish pediatric patients with acute lymphoblastic leukemia. J Pediatr. 2020;216:150–7 e1. doi:10.1016/j.jpeds.2019.09.024
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Liu HC, et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):536–539. doi:10.1038/tpj.2015.75
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang XD, Chao K, et al. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn’s disease. Aliment Pharmacol Ther. 2016;44(9):967–975. doi:10.1111/apt.13796
   PubMed Web of Science ®Google Scholar
• Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16(8):891–903. doi:10.2217/pgs.15.29
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015;171(1):109–115. doi:10.1111/bjh.13518
   PubMed Web of Science ®Google Scholar